21 completed, 5 terminated, 4 recruiting, 2 active not recruiting. 33 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 33 | Completed 21, Terminated 5, Recruiting 4, Active not recruiting 2, Withdrawn 1 |
Follow ETOP IBCSG Partners Foundation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy Cemiplimab - Non-Small Cell Lung Cancer | Phase 3 | Recruiting | ETOP IBCSG Partners Foundation | 390 | 2026-01-12 | 2026-10-14 |
| A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer. Adjuvant durvalumab - Non Small Cell Lung Cancer | Phase 3 | Recruiting | ETOP IBCSG Partners Foundation | 290 | 2025-01-15 | 2026-05-14 |
| Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) Elacestrant, Tamoxifen, Letrozole 2.5mg - ER-positive Breast Cancer, HER2-negative Breast Cancer | Phase 3 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 220 | 2023-12-15 | 2026-10-07 |
| Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer Stereotactic radiosurgery, Immune checkpoint inhibitor - Non-Small Cell Lung Cancer, Melanoma | Phase 3 | Recruiting | ETOP IBCSG Partners Foundation | 180 | 2022-11-30 | 2026-04-27 |
| Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET) Trastuzumab, Alpelisib, Fulvestrant - Advanced Breast Cancer | Phase 3 | Terminated | Spanish Breast Cancer Research Group | 27 | 2021-09-14 | 2026-10-15 |
| Sacituzumab Govitecan in Primary HER2-negative Breast Cancer Capecitabine, Carboplatin, Cisplatin - HER2-negative Breast Cancer, Triple Negative Breast Cancer | Phase 3 | Active not recruiting | GBG Forschungs GmbH | 1332 | 2020-10-28 | 2026-04-22 |
| Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer Palbociclib 125mg, Standard endocrine therapy - Breast Cancer Recurrent | Phase 3 | Active not recruiting | ETOP IBCSG Partners Foundation | 405 | 2019-08-27 | 2026-09-03 |
| BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma Carboplatin, Pemetrexed, Bevacizumab - Pleural Mesothelioma Malignant Advanced | Phase 3 | Completed | ETOP IBCSG Partners Foundation | 400 | 2019-04-30 | 2026-07-22 |
| PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma Pembrolizumab, Gemcitabine, Vinorelbine - Pleural Mesothelioma Malignant Advanced | Phase 3 | Completed | ETOP IBCSG Partners Foundation | 144 | 2017-09-12 | 2026-08-24 |
| Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy Denosumab, None, standard chemotherapy only - Lung Cancer Non-small Cell Stage IV | Phase 3 | Terminated | ETOP IBCSG Partners Foundation | 595 | 2015-01-06 | 2026-09-08 |
| Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®. Erlotinib, Docetaxel - Carcinoma, Non-Small-Cell Lung | Phase 3 | Completed | ETOP IBCSG Partners Foundation | 81 | 2012-08-01 | 2026-08-26 |
| A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer metformin hydrochloride, placebo - Breast Cancer | Phase 3 | Completed | Canadian Cancer Trials Group | 3649 | 2010-08-13 | 2023-09-13 |
| Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02 Tamoxifen, triptorelin, Exemestane - Breast Cancer, Fatigue | Phase 3 | Completed | ETOP IBCSG Partners Foundation | 86 | 2007-12-01 | 2016-07-25 |
| Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer Letrozole - Breast Cancer | Phase 3 | Completed | ETOP IBCSG Partners Foundation | 4884 | 2007-08-01 | 2026-10-23 |
| Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer cyclophosphamide, methotrexate, pegylated liposomal doxorubicin hydrochloride - Breast Cancer | Phase 3 | Terminated | ETOP IBCSG Partners Foundation | 77 | 2005-08-01 | 2021-02-23 |
| Cognitive Function in Postmenopausal Women With Breast Cancer Receiving Hormone Therapy on Clinical Trial IBCSG-1-98 cognitive assessment, fatigue assessment and management, psychologic distress - Breast Cancer, Cognitive/Functional Effects | Phase 3 | Completed | ETOP IBCSG Partners Foundation | 135 | 2005-04-01 | 2012-07-27 |
| Fingernails in Evaluating Bone Health in Postmenopausal Women With Breast Cancer Undergoing Hormone Therapy on Clinical Trial IBCSG-1-98 spectroscopy - Breast Cancer, Osteoporosis | Phase 3 | Terminated | ETOP IBCSG Partners Foundation | 60 | 2005-04-01 | 2012-07-27 |
| Bone Density and Bone Loss in Postmenopausal Women With Breast Cancer Receiving Treatment in Clinical Trial IBCSG-1-98 laboratory biomarker analysis, Dual energy X-ray absorptiometry (DEXA), Spine X-ray - Breast Cancer, Osteoporosis | Phase 3 | Completed | ETOP IBCSG Partners Foundation | 458 | 2004-05-01 | 2012-07-27 |
| Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Exemestane, Laboratory Biomarker Analysis, Oophorectomy - Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor | Phase 3 | Completed | ETOP IBCSG Partners Foundation | 3066 | 2003-12-17 | 2026-08-26 |
| Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer exemestane, tamoxifen, triptorelin - Breast Cancer | Phase 3 | Completed | ETOP IBCSG Partners Foundation | 2672 | 2003-11-03 | 2026-02-06 |
Showing 20 of 33. Sign in to see all of them.
Breast Neoplasms (24) · Carcinoma, Non-Small-Cell Lung (5) · Breast Carcinoma In Situ (3) · Osteoporosis (3) · Fatigue (2) · Triple Negative Breast Neoplasms (2) · Breast Neoplasms, Male (1) · Carcinoma, Ductal, Breast (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Infertility (1) · Melanoma (1) · Sleep Wake Disorders (1)
Tamoxifen (9) · exemestane (6) · Cyclophosphamide (5) · Gonadotropin-Releasing Hormone (4) · Letrozole (4) · Radiotherapy (4) · Triptorelin Pamoate (4) · Epirubicin (3) · Methotrexate (3) · Anastrozole (2) · Capecitabine (2) · Carboplatin (2) · Doxorubicin (2) · Drug Therapy (2) · Ovariectomy (2)
Switzerland (29) · Italy (20) · Belgium (14) · Spain (14) · Australia (13) · France (12) · United Kingdom (12) · Hungary (11) · Austria (9) · Canada (8) · New Zealand (8) · South Africa (8) · Sweden (8) · Germany (7) · Ireland (7)
Kelly-Anne Phillips (3) · Rolf Stahel, MD (3) · Diana Crivellari, MD (2) · James N. Ingle, MD (2) · Juerg Bernhard, PhD (2) · Marco Colleoni, MD (2) · Martine J. Piccart-Gebhart, MD, PhD (2) · Olivia Pagani, MD (2) · Paul E. Goss, MD, PhD (2) · Silvana Martino, DO (2) · Solange Peters, MD-PhD (2) · Stefan Aebi, MD (2) · Alessandra Curioni-Fontecedro, MD (1) · Andrea Decensi, MD (1) · Ann H. Partridge, MD, MPH (1)
PMID 24881463, PMID 26092816, PMID 27044936, PMID 28379421, PMID 28911092, PMID 29863451, PMID 31618131, PMID 33853037, PMID 36521078, PMID 40986647, PMID 41637791, PMID 10076722, PMID 10458221, PMID 14551341, PMID 14962527, PMID 16145047, PMID 16157934, PMID 16236737, PMID 16344321, PMID 16382061, PMID 16421418, PMID 16541302, PMID 16730270, PMID 16822845, PMID 17200148, PMID 17208639, PMID 17301074, PMID 17452676, PMID 17492927, PMID 17646669, PMID 17679725, PMID 17912636, PMID 17998546, PMID 18083065, PMID 18279765, PMID 18296421, PMID 18332043, PMID 18332471, PMID 18332474, PMID 18332475, PMID 18364505, PMID 18650162, PMID 18784962, PMID 18981464, PMID 19096768, PMID 19243946, PMID 19364966, PMID 19468030, PMID 19474112, PMID 19528136
2005 (5), 2004 (2), 2018 (2), 2016 (1), U10CA025224 (1), U10CA037429 (1), U10CA077202 (1), U24CA075362 (1)